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Abstract
Induced pluripotent stem cells (IPSCs), with their unlimited regenerative capacity,
carry the promise for tissue replacement to counter age‐related decline. However,
attempts to realize in vivo iPSC have invariably resulted in the formation of ter-
atomas. Partial reprogramming in prematurely aged mice has shown promising
results in alleviating age‐related symptoms without teratoma formation. Does partial
reprogramming lead to rejuvenation (i.e., “younger” cells), rather than dedifferentia-
tion, which bears the risk of cancer? Here, we analyse the dynamics of cellular age
during human iPSC reprogramming and find that partial reprogramming leads to a
reduction in the epigenetic age of cells. We also find that the loss of somatic gene
expression and epigenetic age follows different kinetics, suggesting that they can be
uncoupled and there could be a safe window where rejuvenation can be achieved
with a minimized risk of cancer.
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1 | INTRODUCTION, RESULTS AND
DISCUSSION
The human aging process is accompanied by multiple degenerative
diseases. Our understanding of such aging related disorders is, nev-
ertheless, fragmented, and the existence and nature of a general
underlying cause are still much debated (Faragher, 2015; Gladyshev
& Gladyshev, 2016). The generation of induced pluripotent stem
cells (iPSCs) allows the reprogramming of somatic cells back to an
embryonic stem cell (ESC)‐like state with an unlimited regenerative
capacity. This has led to multiple strategies for tissue replacement in
degenerative diseases (Takahashi et al., 2007). Clinical application of
iPSCs, however, is at its infancy (Singh, Kalsan, Kumar, Saini, &
Chandra, 2015; Soria‐Valles et al., 2015; Takahashi & Yamanaka,
2016), and the potency of iPSCs bears risks, not least cancer induc-
tion. For example, in vivo experiments with iPSCs have shown that
continuous expression of Yamanaka factors (Oct4, Sox2, Klf4 and
c‐Myc, thus OSKM) in adult mice invariably leads to cancer (Abad
et al., 2013; Ohnishi et al., 2014).
To avoid this risk, a parallel concept of epigenetic rejuvenation
has been proposed: the aging process in cells can be reversed whilst
avoiding dedifferentiation (Manukyan & Singh, 2012; Singh &
Zacouto, 2010). In other words, an old dysfunctional heart cell could
be rejuvenated without the need for it to be passed through an
embryonic/iPSC state. The concept of epigenetic rejuvenation
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requires that rejuvenation and dedifferentiation each follow a dis-
tinct pathway. Nevertheless, it is not well understood whether reju-
venation and dedifferentiation are invariably intertwined, or instead
whether it is possible to manipulate age without risking dedifferenti-
ation.
The epigenetic rejuvenation potential of partial reprogramming
with OSKM factors was previously shown by the forced expression
of OSKM+LIN28 in senescent human fibroblasts, which led to recov-
ering the high mobility of histone protein 1β by day 9, a feature
characteristic for young fibroblasts (Manukyan & Singh, 2014).
Ocampo et al. further demonstrated that partial reprogramming by
transient cyclic induction of OSKM ameliorates signs of aging and
extends lifespan in progeroid mice, with no resulting teratoma for-
mation (Ocampo et al., 2016). This established partial reprogramming
as a promising candidate intervention for age‐related disease. Esti-
mating epigenetic age, which is a promising molecular proxy for bio-
logical age (Jylhävä, Pedersen, & Hägg, 2017; Wagner, 2017), was,
however, not possible to measure in mice at the time of the Ocampo
study. This has left the nature (i.e., dedifferentiation/rejuvenation) of
the described cellular changes unexplored:
1. Does the epigenetic remodelling seen truly reflect rejuvenation
(i.e., a reduction in cellular/tissue age)? If so, can we observe a
decrease in epigenetic age in partially reprogrammed human
cells?
2. What is the extent of rejuvenation upon reaching a partially
reprogrammed state (e.g., years of epigenetic age decrease)?
3. What are the dynamics of dedifferentiation in early reprogram-
ming?
A major obstacle in understanding the relation between differ-
entiation and aging has been our inability to accurately measure
cellular age with a high correlation to the chronological age of the
organism. However, over the last five years, a number of age pre-
dictors have been developed, the most accurate of which utilize
DNA methylation (known as epigenetic clocks) (Hannum et al.,
2013; Horvath, 2013; Horvath et al., 2018; Levine et al., 2018;
Weidner et al., 2014), with the first Horvath multitissue age predic-
tor being the most widely applicable and used (r = 0.96). This “Hor-
vath clock” shows the highest correlation to chronological age,
predicting the age (or epigenetic age, eAge) of multiple tissues with
a median error of 3.6 years (Horvath, 2013). eAge is distinct from
and poorly correlated with other age‐related biomarkers, such as
senescence and telomere length, which have been shown to corre-
late independently with the process of aging (Lowe, Horvath, &
Raj, 2016; Marioni et al., 2016). Moreover, an acceleration of epi-
genetic age as measured by the “Horvath clock” is associated with
a higher risk of all‐cause mortality (Christiansen et al., 2016; Mari-
oni et al., 2015; Perna et al., 2016), premature aging syndromes
(Down and Werner) (Horvath et al., 2015; Maierhofer et al., 2017),
frailty and menopause (Breitling et al., 2016; Levine et al., 2016).
All of these studies suggest that eAge may capture a degree of
biological aging.
To understand the dynamics of eAge during reprogramming, we
applied Horvath's multitissue age predictor over a previously pub-
lished reprogramming time course on human dermal fibroblasts
(HDFs) (Horvath, 2013; Ohnuki et al., 2014). After OSKM transfec-
tion, successfully transformed subpopulations were isolated and
analysed at regular time points during 49 days for gene expression
and DNA methylation (detailed schematic shown in Supporting Infor-
mation Figure S1). Epigenetic rejuvenation, that is, decrease in eAge,
commenced between days 3 and 7 after OSKM transduction in the
partially reprogrammed TRA‐1‐60 (+) cells (characterized in Tanabe,
Nakamura, Narita, Takahashi, & Yamanaka, 2013) and continued
steadily until day 20, when eAge was stably reset to zero (Figure 1a).
A broken stick model (comprising two linear regressions joined at a
break point) showed a good fit to the observed data starting from
day 3 and measured a steady decrease with 3.8 years per day until
day 20 (SE 0.27, p = 3.8 × 10−7) (Figure 1a). The TRA‐1‐60 (+) cell
populations at days 7 and 11 have been previously characterized as
“partially reprogrammed” for their high expression of pluripotency
markers but also high reversion rates towards somatic state (Tanabe
et al., 2013). Therefore, the observed eAge decline at days 7 and 11
suggests that partial reprogramming can indeed be considered a reju-
venation mechanism in human cells.
Horvath's multitissue age predictor is the most accurate and
widely used for various cell types and tissues (Wagner, 2017). Nev-
ertheless, we calculated eAge from alternative DNA methylation‐
based age predictors: four tissue‐specific clocks (Hannum et al.,
2013; Horvath et al., 2018; Weidner et al., 2014), one that incorpo-
rates clinical measures, called PhenoAge (Levine et al., 2018), and
individual CpGs previously correlated with age (Garagnani et al.,
2012). All clocks consistently reached the point of reset to their iPSC
eAge at day 20, despite the cells not being fully reprogrammed
before day 28 (Ohnuki et al., 2014) (Supporting Information Fig-
ure S2). Again, eAge showed a steady decline from day 3 to day 20
in the skin and blood and Weidner 99 CpG clocks, PhenoAge
declined from day 7 to day 20, whilst the Hannum and Weidner 3
CpG clocks did not produce informative trajectories. Overall, eAge
values and “years” of decrease varied between the clocks (actual
chronological age of HDF donors is not available for reference) (Sup-
porting Information Figure S2). The highest age associated individual
CpG (ELOVL2’s cg16867657) showed a similar trajectory to the Hor-
vath eAge decline; however, the remaining CpGs produced inconsis-
tent trajectories (Supporting Information Figure S2). The observed
differences are not surprising, given that the alternative clocks were
validated for blood (Hannum et al., 2013; Weidner et al., 2014),
forensic applications (Horvath et al., 2018), whole organisms (Levine
et al., 2018) or various tissues as for the individual CpGs (Garagnani
et al., 2012).
In Ocampo et al. partial reprogramming was achieved after just
two days of OKSM induction in mice carrying an inducible OSKM
transgene (Ocampo et al., 2016). However, such “secondary” systems
for direct reprogramming are known to have up to 50‐fold higher
efficiency and accelerated kinetics in comparison with virally trans-
duced in vitro systems (Wernig et al., 2008). To facilitate comparison
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to other systems and associate eAge with intermediate states in the
reprogramming trajectory, we compared it to gene expression mea-
sured in the same samples. We analysed corresponding microarray
expression data for 19 well‐established pluripotency marker genes
(Table 1 and Supporting Information Figure S3) as a proxy for reach-
ing a mature pluripotent state (Boyer et al., 2005; Cai et al., 2006;
Galan et al., 2013; Ginis et al., 2004; Mallon et al., 2013). We statis-
tically clustered the expression patterns of those genes (Genolini
et al. 2015), which resulted in two composite trajectories. These fol-
lowed previously described expression dynamics of early (cluster 1)
and late (cluster 2) activated pluripotency genes (Figure 1a) (Buganim
et al., 2012; Chung et al., 2014; Takahashi & Yamanaka, 2016; Tan-
abe et al., 2013). Pluripotency gene cluster 1 included NANOG,
SALL4, ZFP42, TRA‐1‐60, UTF1, DPPA4 and LEFTY2, and their expres-
sion increased dramatically within the first 10 days and then estab-
lished stable pluripotency expression levels by day 20. In contrast,
pluripotency gene cluster 2 (containing late expressing genes such as
LIN28, ZIC3 and DNMT3B) elevated expression more slowly and
reached stable pluripotency levels by day 28 (Chung et al., 2014;
Tanabe et al., 2013). Interestingly, eAge resets to zero at the same
time that the genes in cluster 1 reached their pluripotent state
levels, which temporally precedes full pluripotency. This also coin-
cided with a peak in expression of a number of embryonic develop-
mental genes between days 15 and 20, and might suggest that the
reset marks a point where the cells reach an embryonic‐like state
but are not yet fully pluripotent (Table 1 and Supporting Information
Figure S4). In summary, eAge decline is observed well within the first
wave of pluripotency gene expression.
Therapeutic partial reprogramming will depend on rejuvenation
with minimal dedifferentiation, which carries the risk of malignancies.
We studied the dynamics of fibroblast gene downregulation as a
proxy for the loss of somatic cell identity. The individual trajectories
of 19 commonly used fibroblast marker genes (Chang, Li, & Guo,
2014; Goodpaster et al., 2008; Janmaat et al., 2015; Kalluri &
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F IGURE 1 Dynamics of eAge and gene expression in a 49‐day HDF reprogramming time course. (a) Left Y axis: eAge trajectory of
Horvath's multitissue age predictor calculated from DNA methylation arrays from the following cell populations: day 0 (HDFs), day 3 (OSKM‐
expressing EGFP (+) HDFs), day 7, 11, 15, 20 and 28 (human pluripotency marker TRA‐1–60 (+) cells at intermediate stages of reprogramming),
and fully reprogrammed iPSCs from days 35, 42 and 49. Data were fit with a broken stick model composed of two linear sections. Error bars
represent SD. Measured rate (years per day) of eAge decrease [day 3 – day 20] = −3.8, SE 0.27, p = 3.8 × 10−7. Right Y axis: Composite gene
expression trajectories of key pluripotency markers statistically clustered as per Genolini, Alacoque, and Marianne Sentenac (2015). Microarray
expression data were obtained for the same time points and cell subpopulations as for eAge. Relative expression values were log2‐transformed
and presented as arbitrary units starting from “0” for “day 0” to “1” for “day 49.” Error bars represent SD. (b) Left Y axis: Composite gene
expression trajectories of key fibroblast markers generated as described for the pluripotency markers in (a). Relative expression values were
presented as arbitrary units starting from “1” for “day 0” to “0” for “day 49.” Right Y axis: eAge as in (a, left Y axis), without SD
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Zeisberg, 2006; MacFadyen et al., 2005; Pilling, Fan, Huang, Kaul, &
Gomer, 2009; Zhou, Yang, Randall Wickett, & Zhang, 2016) (Table 1
and Supporting Information Figure S5) clustered into three compos-
ite expression patterns, two of which (clusters 2 and 3) went into an
immediate decline after OSKM induction (Figure 1b). However, one
fibroblast‐specific cluster (cluster 1) remained stable in its expression
for the first 15 days. Interestingly, after day 7, fibroblast‐specific
gene expression in clusters 2 and 3 stopped declining and plateaued
until day 15, coinciding with a peak in expression of senescence
markers between days 11 and 15 (Supporting Information Figure S6).
Vimentin (VIM), for example, remained at 60% of maximal expression
until day 15 of reprogramming, similarly to FAP, CD248 and COL1A2
TABLE 1 List of pluripotency and fibroblast marker genes used in gene expression clusters
Marker Gene Protein name Accession Cluster
Pluripotency NANOG Nanog homeobox A_23_P204640 1 (early)
Pluripotency REX1 (ZFP42) Zinc Finger Protein 42 A_23_P395582 1 (early)
Pluripotency TRA−1–60/81 (PODXL) Podocalyxin A_23_P215060 1 (early)
Pluripotency UTF1 Undifferentiated embryonic cell transcription factor 1 A_33_P3294217 1 (early)
Pluripotency DPPA4 Developmental pluripotency associated 4 A_23_P380526 1 (early)
Pluripotency TDGF1 (CRIPTO) Teratocarcinoma‐derived growth factor 1 A_23_P366376 1 (early)
Pluripotency SALL4 Spalt‐like transcription factor 4 A_23_P109072 1 (early)
Pluripotency LEFTY1 Left–right determination factor 1 A_23_P160336 1 (early)
Pluripotency LEFTY2 Left–right determination factor 2 A_23_P137573 1 (early)
Pluripotency DNMT3A DNA methyl‐transferase 3A A_23_P154500 1 (early)
Pluripotency TFCP2L1 Transcription factor CP2‐like 1 A_23_P5301 1 (early)
Pluripotency TERF1 Telomeric repeat binding factor (NIMA‐interacting) 1 A_23_P216149 2 (late)
Pluripotency DPPA5 Developmental pluripotency associated 5 A_32_P233950 2 (late)
Pluripotency TERT Telomerase reverse transcriptase A_23_P110851 2 (late)
Pluripotency ZIC3 Zic family member 3 A_23_P327910 2 (late)
Pluripotency LIN28a LIN28 homolog A A_23_P74895 2 (late)
Pluripotency LIN28b LIN28 homolog B A_33_P3220615 2 (late)
Pluripotency LECT1 Leukocyte cell derived chemotaxin 1 A_23_P25587 2 (late)
Pluripotency DNMT3B DNA methyl‐transferase 3B A_23_P28953 2 (late)
Fibroblast COL3A1 Pro‐collagen a2(III) A_24_P935491 1
Fibroblast FSP‐1 Fibroblast surface protein A_23_P94800 1
Fibroblast TGFB3 Transforming growth factor beta 3 A_23_P88404 1
Fibroblast TGFB2 Transforming growth factor beta 2 A_24_P402438 1
Fibroblast COL1A2 Pro‐collagen a2(I) A_24_P277934 2
Fibroblast ITGA1 Integrin a1b1 (VLA‐1) A_33_P3353791 2
Fibroblast DDR2 Discoidin‐domain‐receptor‐2 A_23_P452 2
Fibroblast P4HA3 Prolyl 4‐hydroxylase A_24_P290286 2
Fibroblast THY1 Thy‐1 cell surface antigen; CD90 A_33_P3280845 2
Fibroblast FAP Fibroblast activation protein A_23_P56746 2
Fibroblast CD248 Endosialin, TEM1 A_33_P3337485 2
Fibroblast VIM Vimentin A_23_P161190 2
Fibroblast COL1A1 Pro‐collagen a1(I) A_33_P3304668 3
Fibroblast ITGA5 Integrin a5b1 A_23_P36562 3
Fibroblast P4HA1 Prolyl 4‐hydroxylase A_33_P3214481 3
Fibroblast P4HA2 Prolyl 4‐hydroxylase A_33_P3394933 3
Fibroblast TGFB1 Transforming growth factor beta 1 A_24_P79054 3
Fibroblast HSP47 Serpin family H member 1, SERPINH1 A_33_P3269203 –
Fibroblast CD34 Hematopoietic progenitor cell antigen A_23_P23829 –
Note. Key pluripotent marker genes were selected from Ginis et al. (2004); Cai et al. (2006); Mallon et al. (2013); Galan et al. (2013); Boyer et al.
(2005). Fibroblast marker genes were selected from Kalluri and Zeisberg (2006); Zhou et al. (2016); Janmaat et al. (2015); Pilling et al. (2009); Chang
et al. (2014); Goodpaster et al. (2008); MacFadyen et al. (2005).
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in cluster 2 (Supporting Information Figure S5). After day 15, fibrob-
last gene expression declined rapidly in all three clusters, and only
by day 35 had all reached ESC expression levels, marking a complete
loss of somatic identity (Figure 1b). Cluster 1, which contains the
well‐described indicators of fibroblast identity FSP1, COL3A1 and
TGFB2/3 (Kalluri & Zeisberg, 2006), showed the slowest decline and
was also the last to reach ESC expression levels. In summary, we
found that a number of fibroblast‐specific genes maintained high
expression levels until day 15, by which time a substantial drop in
eAge has been observed.
Epigenetic rejuvenation or the reversal of cellular age is a
promising concept as it could avoid the oncogenic risks associated
with dedifferentiation. Here, we analysed a reprogramming time‐
course on HDFs and show that eAge declines in partially repro-
grammed cells before their somatic identity is entirely lost.
It is well established that partial reprogramming happens within
an early, reversible phase during the iPSC reprogramming time‐
course, which involves the stochastic activation of pluripotency
genes. It is followed by a more deterministic maturation phase with
predictable order of gene expression changes, where cell fate is
firmly bound towards pluripotency (Smith, Sindhu, & Meissner,
2016; Takahashi & Yamanaka, 2016). Indeed, it has been shown
that mouse fibroblasts fail to become iPSC and revert to their orig-
inal somatic state if OSKM expression is discontinued during the
initial stochastic phase (Brambrink et al., 2008; Stadtfeld, Maherali,
Breault, & Hochedlinger, 2008). Previously, Tanabe et al. showed
that TRA‐1‐60 (+) cells at reprogramming days 7 and 11 have not
yet reached maturation and are partially reprogrammed (Tanabe
et al., 2013) but our analysis already shows a decrease in their
eAge according to multiple age predictors (Figure 1a and Support-
ing Information Figure S2). We have also shown that a large pro-
portion of fibroblast marker genes maintain relatively high levels of
expression until day 15 (Figure 1b and Supporting Information Fig-
ure S5). Nearly, unchanged levels of expression on day 15 were
previously also shown for a large proportion of somatic genes (Tan-
abe et al., 2013). Together with increased senescence gene expres-
sion between days 11 and 15 (Supporting Information Figure S6),
this likely contributes to the high propensity of partially repro-
grammed TRA‐1‐60 (+) cells to revert back to somatic phenotype
before day 15 in the time‐course (Tanabe et al., 2013). Interest-
ingly, the stepwise decline of fibroblast gene expression coinciding
with a peak in expression of senescence genes seems to delay the
loss of somatic identity but not the expression of pluripotency
genes. Taken together, the different dynamics between the
stepwise fibroblast expression and the linear decline in eAge
further indicate that dedifferentiation and epigenetic rejuvenation
can be uncoupled.
Our data suggest a window of opportunity within the uncommit-
ted reprogramming phase, where a decline of eAge happens along-
side partial maintenance of fibroblast gene expression. A deeper
understanding of the kinetics of rejuvenation will be required to
master therapeutic partial reprogramming, since any progress of ded-
ifferentiation, even in a small subpopulation, carries the risk of
malignancies. Our bulk expression analysis does not allow for a pre-
cise definition of the safe rejuvenation boundaries, and further
experiments on a single cell level and in in vivo conditions are
needed to determine a safe epigenetic rejuvenation window in dif-
ferent reprogramming systems. Upon defining safe boundaries, con-
sideration should also be given to the steep decline of eAge, which
resets to zero well ahead of the establishment of a pluripotent state,
according to a number of age predictors (Supporting Information Fig-
ure S2). Most likely, this marks the point of reaching prenatal or
embryonic stage, as suggested by the peak in expression of key
developmental genes (Supporting Information Figure S4).
The extent of epigenetic rejuvenation in years (human) or
months (mouse), which can be achieved through partial reprogram-
ming, also needs further attention and will most likely differ with the
different reprogramming systems. The “Horvath clock” shows up to
10 years of rejuvenation in Ohnuki et al.’s system by day 7 and
another 10 + years by day 11. However, the intrinsic median estima-
tion error of 3.6 years in this age predictor, the varying eAge rejuve-
nation values between the different age predictors and the
intrareplicate biological variation seen from the large error bars high-
light the need for more experiments and repetitions before this is
established with a higher certainty.
Despite the obvious differences in reprogramming kinetics, our
results also suggest that the improvements observed by Ocampo
et al. in their OSKM‐inducible secondary reprogramming system
might be due to epigenetic rejuvenation. It remains to be shown
how stable in time the rejuvenated phenotype is in either of the sys-
tems. Further analysis is also needed regarding the effect of partial
reprogramming on adult stem cells or premalignant cells, which have
already shown a higher propensity of transforming to malignancy
(Abad et al., 2013; Ohnishi et al., 2014). It is possible that a prema-
lignant phenotype could be attenuated or amplified by partial repro-
gramming. In summary, our findings reveal exciting possibilities but
also open a number of questions and highlight areas that need fur-
ther attention.
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